scholarly journals SP904IMPACT OF VITAMIN D SUPPLEMENTATION ON CALCIUM BLOOD LEVEL, URINE CALCIUM EXCRETION AND STONE FORMATION DYNAMICS IN PATIENTS WITH IDIOPATHIC HYPERCALCIURIA- PRELIMINARY REPORT

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii674-iii674
Author(s):  
Joanna Milart ◽  
Katarzyna Jobs ◽  
Anna Jung
Keyword(s):  
Vitamin D ◽  
Blood Level ◽  
Preliminary Report ◽  
Stone Formation ◽  
Vitamin D Supplementation ◽  
Idiopathic Hypercalciuria ◽  
Calcium Excretion ◽  
Urine Calcium ◽  
Formation Dynamics ◽  
Urine Calcium Excretion

Calcium stones

2015 ◽  
Author(s):  
David A. Bushinsky ◽  
Orson Moe
Keyword(s):  
Risk Factors ◽  
Stone Formation ◽  
Epidemiological Studies ◽  
Idiopathic Hypercalciuria ◽  
Calcium Excretion ◽  
Urine Calcium ◽  
Calcium Stones ◽  
Renal Tubular ◽  
Urine Calcium Excretion ◽  
Predisposing Conditions

Key predisposing factors in calcium stone formation are idiopathic hypercalciuria, primary hyperparathyroidism, and hyperoxaluria (dietary, enteric, idiopathic, sometimes genetic). These are described in detail. Other predisposing conditions include renal tubular acidosis, and risk factors identified in epidemiological studies such as hypocitraturia, increased urinary urate. is defined as an excess of urine calcium excretion without a discernible metabolic cause.

scholarly journals Effect of Vitamin D Treatment on Dynamics of Stones Formation in the Urinary Tract and Bone Density in Children with Idiopathic Hypercalciuria

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2521 ◽  
Author(s):  
Joanna Milart ◽  
Aneta Lewicka ◽  
Katarzyna Jobs ◽  
Agata Wawrzyniak ◽  
Małgorzata Majder-Łopatka ◽  
...  
Keyword(s):  
Vitamin D ◽  
Urinary Tract ◽  
Bone Density ◽  
Calcium Concentration ◽  
Vitamin D Supplementation ◽  
Urinary Calcium ◽  
Idiopathic Hypercalciuria ◽  
Calcium Excretion ◽  
Blood And Urine Samples ◽  
The Impact

Vitamin D supplementation in patients with urolithiasis and hypercalciuria is considered to be unsafe. We analyzed the impact of vitamin D supplementation on selected health status parameters in children with idiopathic hypercalciuria. The study included 36 children with urolithiasis resulting from excessive calcium excretion. The level of calcium and 25(OH)D (hydroxylated vitamin D - calcidiol) in serum, urinary calcium excretion and the presence of stones in urinary tract were assessed prospectively. Blood and urine samples were collected at the time when the patient was qualified for the study and every three months up to 24 month of vitamin D intake at a dose of 400 or 800 IU/day. At time zero and at 12, and 24 months of vitamin D supplementation, densitometry was performed. Supplementation with vitamin D caused a statistically significant increase in the concentration of 25(OH)D in serum. There were no significant changes in calcium concentration in serum, excretion of calcium in urine but also in bone density. There was no significant increase in the risk of formation or development of stones in the urinary tract. Supplementation with vitamin D (400–800 IU/day) in children with idiopathic hypercalciuria significantly increases 25(OH)D concentration, does not affect calciuria, but also does not improve bone density.

scholarly journals Urine calcium excretion predicts bone loss in idiopathic hypercalciuria

2006 ◽  
Vol 70 (8) ◽  
pp. 1463-1467 ◽  
Author(s):  
J.R. Asplin ◽  
S. Donahue ◽  
J. Kinder ◽  
F.L. Coe
Keyword(s):  
Bone Loss ◽  
Idiopathic Hypercalciuria ◽  
Calcium Excretion ◽  
Urine Calcium ◽  
Urine Calcium Excretion

scholarly journals Calcium and Vitamin D Supplementation and Their Association with Kidney Stone Disease: A Narrative Review

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4363
Author(s):  
Matteo Bargagli ◽  
Pietro Manuel Ferraro ◽  
Matteo Vittori ◽  
Gianmarco Lombardi ◽  
Giovanni Gambaro ◽  
...  
Keyword(s):  
Vitamin D ◽  
Kidney Stone ◽  
Stone Formation ◽  
Vitamin D Supplementation ◽  
Stone Disease ◽  
Normal Body Mass Index ◽  
Calcium Excretion ◽  
Kidney Stone Disease ◽  
Low Calcium Diet ◽  
Stone Formers

Kidney stone disease is a multifactorial condition influenced by both genetic predisposition and environmental factors such as lifestyle and dietary habits. Although different monogenic polymorphisms have been proposed as playing a causal role for calcium nephrolithiasis, the prevalence of these mutations in the general population and their complete pathogenetic pathway is yet to be determined. General dietary advice for kidney stone formers includes elevated fluid intake, dietary restriction of sodium and animal proteins, avoidance of a low calcium diet, maintenance of a normal body mass index, and elevated intake of vegetables and fibers. Thus, balanced calcium consumption protects against the risk for kidney stones by reducing intestinal oxalate availability and its urinary excretion. However, calcium supplementation given between meals might increase urinary calcium excretion without the beneficial effect on oxalate. In kidney stone formers, circulating active vitamin D has been found to be increased, whereas higher plasma 25-hydroxycholecalciferol seems to be present only in hypercalciuric patients. The association between nutritional vitamin D supplements and the risk for stone formation is currently not completely understood. However, taken together, available evidence might suggest that vitamin D administration worsens the risk for stone formation in patients predisposed to hypercalciuria. In this review, we analyzed and discussed available literature on the effect of calcium and vitamin D supplementation on the risk for kidney stone formation.

The Effect of Vitamin D Supplementation On Calcium Excretion in Thalassemia

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1029-1029
Author(s):  
Sadana Balachandar ◽  
Rachel Randolph ◽  
Dorothy A. Kleinert ◽  
Sujit Sheth ◽  
Patricia Giardina ◽  
...  
Keyword(s):  
Vitamin D ◽  
Placebo Group ◽  
Dose Group ◽  
Vitamin D Supplementation ◽  
High Dose Group ◽  
Controlled Study ◽  
High Dose ◽  
Calcium Excretion ◽  
Urine Calcium ◽  
Number Of Patients

Abstract Abstract 1029 Purpose of study: Transfusion dependent thalassemia (TM) patients are routinely supplemented with vitamin D due to their increased risk of developing osteoporosis. Recent studies from North America have found that these patients have high rates of vitamin D “deficiency” and “insufficiency,” despite supplementation. The amount of vitamin D supplementation required to raise serum 25 hydroxy-vitamin D (25-OHD) to optimal levels is not known in these patients. Recent studies have linked 25-OHD levels to hypercalciuria and nephrolithiasis in patients with TM. The purpose of this study is to determine the effect of various doses of vitamin D supplementation on vitamin D stores and calcium excretion in TM patients. Description of project: Prospective, single-blind, placebo-controlled study of TM patients followed in the transfusion center at Weill Cornell/New York Presbyterian Hospital. Patients with 25-OHD concentrations between 15–29 ng/mL were eligible for this 3-month study. Subjects were assigned in a block type of enrollment to the “high dose” equivalent of 2,000 IU of vitamin D per day versus placebo. Results: 14 subjects were enrolled, with 8 assigned to the “high dose” group and 6 assigned to the placebo group. The “high dose” group consisted of 6 females, aged 15.2–45.5 years with an average baseline 25-OHD level of 22.4 ng/mL (15–26). The “placebo” group consisted of 4 females, aged 22.5–45.7 years with an average baseline 25-OHD level of 19.8 ng/mL (16–24). After the 3 month study period, hypercalciuria developed more frequently in those treated in the “high dose” group. In the placebo group, hypercalciuria was noted in 1/6 (16.7%) spot urine calcium/creatinine tests and 0/3 (0%) 24 hour urine calcium estimations. In the “high dose” group, the corresponding number of patients based on the same methods of testing were 5/8 (62.5%) and 2/5 (40%). No episodes of hypocalcemia, hypercalcemia or nephrolithiasis occurred in either group. Conclusion: Our findings suggest that “high dose” vitamin D supplementation results in higher rates of hypercalciuria in TM patients. Further studies are necessary to determine the optimal dose of vitamin D supplementation to minimize the risk of osteoporosis while preventing nephrolithiasis in TM patients. Disclosures: No relevant conflicts of interest to declare.

Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial

2019 ◽  
Vol 105 (4) ◽  
pp. 1261-1273 ◽  
Author(s):  
Emma O Billington ◽  
Lauren A Burt ◽  
Marianne S Rose ◽  
Erin M Davison ◽  
Sharon Gaudet ◽  
...  
Keyword(s):  
Vitamin D ◽  
Adverse Events ◽  
Controlled Trial ◽  
Vitamin D Supplementation ◽  
Calcium Excretion ◽  
Hydroxyvitamin D ◽  
Randomized Controlled ◽  
25 Hydroxyvitamin D ◽  
Higher Doses ◽  
Urine Calcium Excretion

Abstract Context More than 3% of adults report vitamin D intakes of 4000 IU/day or more, but the safety of this practice is unknown. Objective The objective of this work is to establish whether vitamin D doses up to 10 000 IU/day are safe and well tolerated. Design The Calgary Vitamin D Study was a 3-year, double-blind, randomized controlled trial. Setting A single-center study was conducted at the University of Calgary, Canada. Participants Participants included healthy adults (n = 373) ages 55 to 70 years with serum 25-hydroxyvitamin D 30 to 125 nmol/L. Interventions Participants were randomly assigned 1:1:1 to vitamin D3 400, 40 000, or 10 000 IU/day. Calcium supplementation was initiated if dietary calcium intake was less than 1200 mg/day. Main Outcome Measures In these prespecified secondary analyses, changes in serum 25-hydroxyvitamin D, calcium, creatinine, 24-hour urine calcium excretion, and incidence of adverse events were assessed. Between-group differences in adverse events were examined using incident rate differences and logistic regression. Results Of 373 participants (400: 124, 4000: 125, 10 000: 124), 49% were male, mean (SD) age was 64 (4) years, and 25-hydroxyvitamin D 78.0 (19.5) nmol/L. Serum calcium, creatinine, and 24-hour urine calcium excretion did not differ between treatments. Mild hypercalcemia (2.56-2.64 mmol/L) occurred in 15 (4%) participants (400: 0%, 4000: 3%, 10 000: 9%, P = .002); all cases resolved on repeat testing. Hypercalciuria occurred in 87 (23%) participants (400: 17%, 4000: 22%, 10 000: 31%, P = .01). Clinical adverse events were experienced by 365 (97.9%) participants and were balanced across treatment arms. Conclusions The safety profile of vitamin D supplementation is similar for doses of 400, 4000, and 10 000 IU/day. Hypercalciuria was common and occurred more frequently with higher doses. Hypercalcemia occurred more frequently with higher doses but was rare, mild, and transient.

Sign in / Sign up

Export Citation Format

Share Document